MedTrace Logo

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

NCT00448799 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-05-13

No results posted yet for this study

Summary

The underlying goal of this study is to assess 123-I AV83 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.

Conditions

  • Alzheimers Disease

Interventions

RADIATION

[123-I] AV-83 Injection and Imaging Procedures

Evaluation of \[123I\] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects

Sponsors & Collaborators

  • Institute for Neurodegenerative Disorders

    collaborator OTHER

  • Molecular NeuroImaging

    lead OTHER

Principal Investigators

  • Danna Jennings, MD · Molecular NeuroImaging

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448799 on ClinicalTrials.gov